Share

September 2021; 8 (5) ArticleOpen Access

Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome

Enric Monreal, Susana Sainz de la Maza, Lucienne Costa-Frossard, Paulette Walo-Delgado, Javier Zamora, José Ignacio Fernández-Velasco, Noelia Villarrubia, Mercedes Espiño, Daniel Lourido, Paloma Lapuente, Inmaculada Toboso, José Carlos Álvarez-Cermeño, Jaime Masjuan, Luisa María Villar
First published July 22, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001047
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
754

Share

Article Information

vol. 8 no. 5 e1047
DOI: 
https://doi.org/10.1212/NXI.0000000000001047
PubMed: 
34301819
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received February 25, 2021
  • Accepted in final form June 14, 2021
  • First Published July 22, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Enric Monreal, MD,
    2. Susana Sainz de la Maza, MD (susanasmc85{at}hotmail.com),
    3. Lucienne Costa-Frossard, MD (lufrossard{at}yahoo.es),
    4. Paulette Walo-Delgado, MD (pauletteesperanz.walo{at}salud.madrid.org),
    5. Javier Zamora, PhD (javierza{at}gmail.com),
    6. José Ignacio Fernández-Velasco, MSc (jfvelasco{at}salud.madrid.org),
    7. Noelia Villarrubia, PhD (noelia.villarrubia{at}salud.madrid.org),
    8. Mercedes Espiño, PhD (mercedes.espino{at}salud.madrid.org),
    9. Daniel Lourido, MD (louridodaniel{at}hotmail.com),
    10. Paloma Lapuente, MD (paloma.lapuente{at}salud.madrid.org),
    11. Inmaculada Toboso, PhD (inma.toboso.delamo{at}gmail.com),
    12. José Carlos Álvarez-Cermeño, PhD (josecarlos.alvarez{at}salud.madrid.org),
    13. Jaime Masjuan, PhD (jaime.masjuan{at}salud.madrid.org) and
    14. Luisa María Villar, PhD (luisamaria.villar{at}salud.madrid.org)
  1. Enric Monreal, MD,
    2. Scientific Advisory Boards:

    1. (1) Sanofi-Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen, funding for travel and speak to conference (2) Roche, funding for travel to conference (3) Almirall, funding for travel to conference (4) Sanofi-Genzyme, funding for travel to conference (5) Novartis, funding for travel to conference (6) Merck, funding for travel to conference

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Lymphocytes subsets ratio to predict autoimmunity in patients treated with Alemtuzumab.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Merck, promotional campaign

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Susana Sainz de la Maza, MD (susanasmc85{at}hotmail.com),
    3. Scientific Advisory Boards:

    1. (1) Almirall (Comercial entity) (2) Merck (Commercial entity) (3) Sanofi-Genzyme (Commercial entity)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen. Commercial entity. Speaker honoraria. (2) Merck. Commercial entity. Speaker honoraria. (3) Roche. Commercial entity. Speaker honoraria. (4) Sanofi-Genzyme. Commercial entity. Speaker honoraria. (5) Teva. Commercial entity. Speaker honoraria.

    Editorial Boards:

    1. NONE

    Patents:

    1. 17 382 331.1. Method for monitoring and predicting the efficacy of treatment in a multiple sclerosis patient España. 20/06/2017. FIBio-HRC.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Lucienne Costa-Frossard, MD (lufrossard{at}yahoo.es),
    4. Scientific Advisory Boards:

    1. received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.

    Editorial Boards:

    1. Editorial Board Member in American Journal of Psychiatry and Neuroscience

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.

    Speakers' Bureaus:

    1. received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Paulette Walo-Delgado, MD (pauletteesperanz.walo{at}salud.madrid.org),
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Patent No. 20382988.2 - 1118 Predictive biomarkers of autoimmunity in patients treated with alemtuzumab

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Javier Zamora, PhD (javierza{at}gmail.com),
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. José Ignacio Fernández-Velasco, MSc (jfvelasco{at}salud.madrid.org),
    7. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Noelia Villarrubia, PhD (noelia.villarrubia{at}salud.madrid.org),
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1)Fondo para la Investigación Sanitaria from the Instituto de Salud Carlos III, the Ministerio de Ciencia e Innovación (Spain) and Fondo Europeo de Desarrollo Regional (FEDER), grant number: RD16/0015/0001, 2019-2021 (2)Fondo para la Investigación Sanitaria from the Instituto de Salud Carlos III, the Ministerio de Ciencia e Innovación (Spain) and Fondo Europeo de Desarrollo Regional (FEDER), grant number: PI18/00572, 2017-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Mercedes Espiño, PhD (mercedes.espino{at}salud.madrid.org),
    9. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Daniel Lourido, MD (louridodaniel{at}hotmail.com),
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Paloma Lapuente, MD (paloma.lapuente{at}salud.madrid.org),
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Inmaculada Toboso, PhD (inma.toboso.delamo{at}gmail.com),
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. José Carlos Álvarez-Cermeño, PhD (josecarlos.alvarez{at}salud.madrid.org),
    13. Scientific Advisory Boards:

    1. Genzyme, Araclon Biotech

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Jaime Masjuan, PhD (jaime.masjuan{at}salud.madrid.org) and
    14. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Luisa María Villar, PhD (luisamaria.villar{at}salud.madrid.org)
    15. Scientific Advisory Boards:

    1. Genzyme, Biogen, Merck, Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Biogen: Funding for travel or speaker honorariaMerck: Funding for travel or speaker honorariaNovartis: Funding for travel or speaker honorariaGenzyme: Funding for travel or speaker honorariaRoche: Funding for travel or speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. Biomarker for selecting good responders to IFN beta in multiple sclerosis

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have received payment for consultancies fromBiogen Idec, Merck, Novartis, (Commercial entities)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Genzyme; Merck; Biogen; Roche

    Research Support, Government Entities:

    1. Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (ISCIII). Grant N. PI18/00572 for the research in MS. Years 2019-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (E.M., S.S.d.l.M., L.C.-F., J.C.Á.-C., J.M.), and Department of Immunology (P.W.-D., J.I.F.-V., N.V., M.E., P.L., I.T., L.M.V.), Hospital Universitario Ramón y Cajal, REEM, IRYCIS; Clinical Biostatistics Unit (J.Z.), Hospital Universitario Ramón y Cajal, IRYCIS, CIBERESP, Madrid, Spain; Institute of Metabolism and System Research (J.Z.), University of Birmingham, United Kingdom; and Department of Radiology (D.L.), Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
  1. Correspondence
    Dr. Monreal enricmonreal{at}outlook.com

Article usage

Article usage: July 2021 to October 2023

AbstractFullPdfSource
Jul 20218772118Highwire
Aug 20211645280Highwire
Sep 20211517363Highwire
Oct 2021915736Highwire
Nov 202188539Highwire
Dec 2021148422Highwire
Jan 202267521Highwire
Feb 202295320Highwire
Mar 202248125Highwire
Apr 202266617Highwire
May 202276215Highwire
Jun 202238422Highwire
Jul 202246212Highwire
Aug 2022105814Highwire
Sep 202277924Highwire
Oct 202276328Highwire
Nov 20221023427Highwire
Dec 202225318Highwire
Jan 202399321Highwire
Feb 202355614Highwire
Mar 202344718Highwire
Apr 202375812Highwire
May 202375622Highwire
Jun 202365013Highwire
Jul 202364313Highwire
Aug 20232578Highwire
Sep 202356921Highwire
Oct 202355511Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles